Clinical trials: Stage II Hypertension
Hypertension
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
- Trial name
- NCT00281580
- Testing
- Amlodipine 5 mg, Telmisartan 20 mg, Telmisartan 40 mg
- Where
- 136 sites in United States, Argentina and 3 more
- Volunteers
- 1,461 people
- Sponsor
- Boehringer Ingelheim
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Intracerebral Hemorrhage
Antihypertensive Treatment of Acute Cerebral Hemorrhage-II
The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months…
- Trial name
- ATACH-II (NCT01176565)
- Testing
- Intravenous nicardipine hydrochloride
- Where
- 171 sites in United States, Canada and 5 more
- Volunteers
- 1,000 people
- Sponsor
- University of Minnesota
Stage 2 Hypertension
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
- Trial name
- VANTAGE (NCT00809926)
- Testing
- Valsartan/aliskiren, Valsartan
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Novartis
Idiopathic Intracranial Hypertension
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
Assessing the safety and effectiveness of a 11-βhydroxysteroid dehydrogenase type 1 inhibitor (AZD4017), in a placebo controlled trial, in acute idiopathic intracranial hypertension (IIH) IIH is a condition of young, overweight…
- Trial name
- IIH:DT (NCT02017444)
- Testing
- AZD4017
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- University of Birmingham
Pulmonary Hypertension
Safety Study of Gleevec® in Children With Pulmonary Hypertension
The purpose of this study is to find out if the drug, Gleevec, is safe and effective in treating children with Pulmonary Hypertension.
- Trial name
- NCT00583115
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Hypertension, Coronary Artery Disease
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery…
- Trial name
- NCT00673075
- Testing
- Nebivolol, Carvedilol
- Where
- 34 sites in United States
- Volunteers
- 39 people
- Sponsor
- Forest Laboratories
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
Safety of SonoVue on Pulmonary Hemodynamics
This is an intra-subject crossover comparative safety study to evaluate the effect of intravenous (IV) bolus injection of SonoVue on pulmonary hemodynamics.
- Trial name
- NCT01306292
- Testing
- SonoVue
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Bracco Diagnostics, Inc
Hypertension, Diabetes Mellitus
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting…
- Trial name
- ASTRIDE (NCT00787605)
- Testing
- Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- Novartis
Stage 2 Systolic Hypertension
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension
This study will compare the antihypertensive efficacy and safety of a valsartan/amlodipine-based treatment with a losartan-based treatment in patients with Stage 2 systolic hypertension (high blood pressure, mean systolic blood…
- Trial name
- EXALT (NCT00931710)
- Testing
- valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
- Where
- United States
- Volunteers
- 488 people
- Sponsor
- Novartis
Hypertension
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
The purpose of the study is to evaluate the efficacy and safety of initial use of a fixed dose combination of aliskiren Hydrochlorothiazide (HCTZ) compared to Hydrochlorothiazide in older population with Stage 2 systolic…
- Trial name
- ACTION (NCT00760266)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients.
- Trial name
- TransformPAH (NCT01647945)
- Testing
- FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Edda Spiekerkoetter
Stage II Hypertension
Candesartan Effect in Second Stage Arterial Hypertension
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
- Trial name
- CAESAR (NCT00621153)
- Testing
- Candesartan Cilexetil, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle…
- Trial name
- NCT02829996
- Testing
- trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Dysautonomia, Familial, Baroreflex Failure Syndrome
Carbidopa for the Treatment of Excessive Blood Pressure Variability
The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated…
- Trial name
- CarbiFD (NCT02553265)
- Testing
- Carbidopa Low-Dose, Carbidopa High-Dose
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- NYU Langone Health